Interestingly, HDAC inhibitors have been proven effective in several types of cancer (Leoni et al., 2002; Bolden et al., 2006; Minucci and Pelicci, 2006) and represent a promising therapy for non-oncological diseases, including neurodegeneration, inflammation and cardiovascular diseases (Pons et al., 2009; Colussi et al., 2010). This evidence concerns the gene HDAC9 and cardiovascular disorder.